NASDAQ:NARI - Inari Medical Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $106.80
  • Forecasted Upside: 66.61 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$64.10
▲ +2.06 (3.32%)

This chart shows the closing price for NARI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inari Medical Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NARI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NARI

Analyst Price Target is $106.80
▲ +66.61% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Inari Medical in the last 3 months. The average price target is $106.80, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 66.61% upside from the last price of $64.10.

This chart shows the closing price for NARI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 polled investment analysts is to buy stock in Inari Medical.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2022Bank of AmericaInitiated CoverageBuy ➝ BuyLow
3/14/2022Canaccord Genuity GroupLower Price Target$102.00 ➝ $96.00High
3/14/2022Canaccord Genuity GroupLower Price TargetBuy$102.00 ➝ $96.00High
2/24/2022Morgan StanleyLower Price TargetOverweight$119.00 ➝ $108.00High
2/24/2022SVB LeerinkBoost Price TargetOutperform$85.00 ➝ $95.00High
11/29/2021BTIG ResearchReiterated RatingBuy$139.00Medium
11/10/2021SVB LeerinkBoost Price TargetOutperform$110.00 ➝ $120.00High
8/11/2021SVB LeerinkLower Price TargetOutperform$126.00 ➝ $110.00High
5/12/2021Morgan StanleyBoost Price TargetOverweight$126.00 ➝ $129.00High
3/10/2021SVB LeerinkBoost Price TargetOutperform$116.00 ➝ $126.00High
3/10/2021Wells Fargo & CompanyBoost Price TargetOverweight$112.00 ➝ $125.00High
3/10/2021Morgan StanleyBoost Price TargetOverweight$85.00 ➝ $126.00High
3/10/2021BTIG ResearchBoost Price TargetBuy$125.00 ➝ $135.00High
1/21/2021BTIG ResearchBoost Price TargetBuy$92.00 ➝ $110.00Low
1/20/2021Wells Fargo & CompanyBoost Price TargetOverweight$79.00 ➝ $112.00Low
12/15/2020Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$79.00Medium
11/18/2020BTIG ResearchInitiated CoverageBuy$92.00High
11/13/2020Morgan StanleyBoost Price TargetOverweight$76.00 ➝ $85.00High
11/13/2020SVB LeerinkBoost Price TargetOutperform$80.00 ➝ $90.00High
10/29/2020Morgan StanleyUpgradeEqual Weight ➝ Overweight$66.00 ➝ $76.00Low
9/28/2020SVB LeerinkInitiated CoverageOutperform$80.00Medium
8/12/2020Morgan StanleyBoost Price TargetEqual Weight$52.00 ➝ $66.00High
6/16/2020Bank of AmericaInitiated CoverageNeutral$56.00Low
6/16/2020Wells Fargo & CompanyInitiated CoverageEqual Weight$49.00Low
6/16/2020Morgan StanleyInitiated CoverageEqual Weight$52.00Low
(Data available from 5/26/2017 forward)

News Sentiment Rating

0.67 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/25/2022
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/26/2022
  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/26/2022

Current Sentiment

  • 4 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Inari Medical logo
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Read More

Today's Range

Now: $64.10
Low: $61.19
High: $64.69

50 Day Range

MA: $78.71
Low: $52.13
High: $93.81

52 Week Range

Now: $64.10
Low: $50.50
High: $100.00

Volume

14,189 shs

Average Volume

652,469 shs

Market Capitalization

$3.41 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Inari Medical?

The following sell-side analysts have issued stock ratings on Inari Medical in the last year: Bank of America Co., BTIG Research, Canaccord Genuity Group Inc., Morgan Stanley, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for NARI.

What is the current price target for Inari Medical?

0 Wall Street analysts have set twelve-month price targets for Inari Medical in the last year. Their average twelve-month price target is $106.80, suggesting a possible upside of 72.1%.
View the latest price targets for NARI.

What is the current consensus analyst rating for Inari Medical?

Inari Medical currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NARI will outperform the market and that investors should add to their positions of Inari Medical.
View the latest ratings for NARI.

How do I contact Inari Medical's investor relations team?

Inari Medical's physical mailing address is 9 Parker Suite 100, Irvine CA, 92618. The company's listed phone number is 877-923-4747 and its investor relations email address is [email protected] The official website for Inari Medical is www.inarimedical.com. Learn More about contacing Inari Medical investor relations.